23 June 2020>: Lab/In Vitro Research
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer
Xiaoqiu Wu 123BEF* , Fangfei Li 123AG** , Yongshu Li 1BF , Yuanyuan Yu 13DF , Chao Liang 13C , Baoting Zhang 4DE , Chuanzong Zhao 56B , Aiping Lu 12378AG* , Ge Zhang 123AG*DOI: 10.12659/MSM.925583
Med Sci Monit 2020; 26:e925583
Figure 1 Validation for gene knock-out and over-expression of PD-L1 in cells. (A) Western blot analysis showed the total PD-L1 expression in MDA-MB-231 cells after gene knock-out and over-expression. Detection of GAPDH was used as a loading control. (B) The PD-L1 mRNA level was analyzed by RT-qPCR. The data for the qPCR experiments are expressed as the mean±SD (** P<0.005, *** P<0.001) normalized with GAPDH mRNA. (C) Flow cytometry analysis of PD-L1 expression on the plasma membrane (anti-PD-L1 antibody, red; IgG, black). GAPDH – glyceraldehyde 3-phosphate dehydrogenase; RT-qPCR – Real-time quantitative PCR analysis.